Apixaban for the Acute Treatment of Venous Thromboembolism in Children

NCT02464969

Last updated date
Study Location
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08901, United States

See if I May Qualify

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Venous Thromboembolism
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0-17
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. 28 days to <18 years of age with a minimum weight of 4 kg at the time of randomization.

2. Presence of an index VTE which is confirmed by imaging.

3. Intention to manage the index VTE with anticoagulation treatment for at least 6 to 12 weeks.

4. Subjects able to tolerate oral feeding, nasogastric (NG), gastric (G) feeding for at least 5 days.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. Anticoagulant treatment for the index VTE for greater than 14 days prior to
randomization.


2. Thrombectomy, thrombolytic therapy, or insertion of a caval filter to treat the index
VTE.


3. A mechanical heart valve.


4. Active bleeding or high risk of bleeding at the time of randomization.


5. Intracranial bleed, including intraventricular hemorrhage, within 3 months prior to
randomization.


6. Abnormal baseline liver function at randomization.


7. Inadequate renal function at the time of randomization.


8. Platelet count <50×109 per L at randomization.


9. Uncontrolled severe hypertension at the time of randomization.


10. Use of prohibited concomitant medication at the time of randomization.


11. Female subjects who are either pregnant or breastfeeding a child.


12. Use of aggressive life-saving therapies such as ventricular assist devices (VAD) or
extracorporeal membrane oxygenation (ECMO) at the time of enrollment.


13. Unable to take oral or enteric medication via the NG or G tube.


14. Known inherited or acquired antiphospholipid syndrome (APS).


15. Known inherited bleeding disorder or coagulopathy with increased bleeding risk (eg,
hemophilia, von Willebrand disease, etc.)

NEED INFO?

For Patients: Please visit the prescreener for more information

All other inquiries: Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Venous ThromboembolismDalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients NCT00445328
  1. Hyderabad, Andhra Pradesh
  2. Ahmedabad, Gujarat
  3. Trichur, Kerala
  4. Indore, Madhya Pradesh
  5. Chennai, Tamil Nadu
  6. Kolkata, West Bengal
  7. Kolkata, West Bengal
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Venous ThromboembolismAn Observational Study On The Safety And Tolerability Of Prolonged Thrombosis Prophylaxis With Fragmin® NCT01046903
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Venous ThromboembolismFragmin for the Treatment of Acute VTE in Pediatric Cancer Patients NCT00952380
  1. Aurora, Colorado
  2. Washington, District of Columbia
  3. Jacksonville, Florida
  4. Jacksonville, Florida
  5. Tampa, Florida
  6. Tampa, Florida
  7. Tampa, Florida
  8. Tampa, Florida
  9. Tampa, Florida
  10. Detroit, Michigan
  11. Kansas City, Missouri
  12. Memphis, Tennessee
  13. El Paso, Texas
  14. El Paso, Texas
  15. Houston, Texas
  16. Houston, Texas
  17. Houston, Texas
  18. Oslo,
  19. Oslo,
  20. Kazan, Republic Tatarstan
  21. Kazan, Republic Tatarstan
  22. Moscow,
  23. Ljubljana,
  24. Ljubljana,
  25. Boadilla del Monte, Madrid
  26. Boadilla del Monte, Madrid
ALL GENDERS
0+
years
MULTIPLE SITES
Venous ThromboembolismApixaban for the Acute Treatment of Venous Thromboembolism in Children NCT02464969
  1. New Brunswick, New Jersey
  2. New Brunswick, New Jersey
  3. Sioux Falls, South Dakota
  4. Sioux Falls, South Dakota
  5. Sioux Falls, South Dakota
  6. Sioux Falls, South Dakota
  7. Haifa,
  8. Birmingham, Alabama
  9. Birmingham, Alabama
  10. Birmingham, Alabama
  11. Phoenix, Arizona
  12. Loma Linda, California
  13. Loma Linda, California
  14. Loma Linda, California
  15. Madera, California
  16. Oakland, California
  17. Oakland, California
  18. Oakland, California
  19. Palo Alto, California
  20. Palo Alto, California
  21. Palo Alto, California
  22. Roseville, California
  23. Sacramento, California
  24. Sacramento, California
  25. San Bernardino, California
  26. San Francisco, California
  27. San Francisco, California
  28. San Francisco, California
  29. Aurora, Colorado
  30. Aurora, Colorado
  31. Hartford, Connecticut
  32. Wilmington, Delaware
  33. Washington, District of Columbia
  34. Hollywood, Florida
  35. Hollywood, Florida
  36. Orlando, Florida
  37. Orlando, Florida
  38. Orlando, Florida
  39. Orlando, Florida
  40. Tampa, Florida
  41. West Palm Beach, Florida
  42. West Palm Beach, Florida
  43. Atlanta, Georgia
  44. Atlanta, Georgia
  45. Atlanta, Georgia
  46. Peoria, Illinois
  47. Indianapolis, Indiana
  48. Indianapolis, Indiana
  49. Indianapolis, Indiana
  50. Iowa City, Iowa
  51. Lexington, Kentucky
  52. New Orleans, Louisiana
  53. Boston, Massachusetts
  54. Ann Arbor, Michigan
  55. Detroit, Michigan
  56. Detroit, Michigan
  57. Jackson, Mississippi
  58. Hackensack, New Jersey
  59. New Brunswick, New Jersey
  60. New York, New York
  61. New York, New York
  62. New York, New York
  63. New York, New York
  64. New York, New York
  65. New York, New York
  66. Syracuse, New York
  67. Durham, North Carolina
  68. Durham, North Carolina
  69. Akron, Ohio
  70. Cincinnati, Ohio
  71. Cleveland, Ohio
  72. Cleveland, Ohio
  73. Columbus, Ohio
  74. Dayton, Ohio
  75. Oklahoma City, Oklahoma
  76. Oklahoma City, Oklahoma
  77. Philadelphia, Pennsylvania
  78. Philadelphia, Pennsylvania
  79. Philadelphia, Pennsylvania
  80. Philadelphia, Pennsylvania
  81. Pittsburgh, Pennsylvania
  82. Charleston, South Carolina
  83. Charleston, South Carolina
  84. Nashville, Tennessee
  85. Nashville, Tennessee
  86. Nashville, Tennessee
  87. Houston, Texas
  88. Houston, Texas
  89. Houston, Texas
  90. San Antonio, Texas
  91. San Antonio, Texas
  92. Salt Lake City, Utah
  93. Seattle, Washington
  94. Milwaukee, Wisconsin
  95. West Allis, Wisconsin
  96. Randwick, New South Wales
  97. Sydney, New South Wales
  98. Innsbruck, Tyrol
  99. Innsbruck,
  100. Wien,
  101. Hamilton, Ontario
  102. Ottawa, Ontario
  103. Berlin,
  104. Duisburg,
  105. Leipzig,
  106. Munchen,
  107. Beer Sheva,
  108. Beer Sheva,
  109. Beer Sheva,
  110. Haifa,
  111. Ramat Gan,
  112. Coimbra,
  113. Lisboa,
  114. Kazan, Republic Tatarstan
  115. Yekaterinburg, Sverdlovsk Region
  116. Moscow,
  117. Moscow,
  118. Boadilla del Monte, Madrid
  119. Barcelona,
  120. Barcelona,
  121. Madrid,
  122. Dnipro,
  123. Kyiv,
  124. Kyiv,
  125. Zaporizhzhia,
  126. Glasgow, Scotland
  127. Newcastle upon Tyne, Tyne & Wear
  128. Cardiff, Wales
  129. Cardiff, Wales
  130. Birmingham, WEST Midlands
  131. Birmingham,
  132. Newcastle Upon Tyne,
ALL GENDERS
0+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Apixaban for the Acute Treatment of Venous Thromboembolism in Children
Official Title  ICMJE A RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATION FOR THE TREATMENT OF A VENOUS THROMBOEMBOLIC EVENT
Brief Summary To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Venous Thromboembolism
Intervention  ICMJE
  • Drug: Apixaban
    Tablet or Solution
  • Drug: Standard of Care
    Unfractionated heparin, low molecular weight heparin, and/or a vitamin K antagonist. For subjects under 2 years of age, standard of care will be limited to unfractionated heparin or low molecular weight heparin.
Study Arms  ICMJE
  • Experimental: Apixaban
    Subjects between 28 days to <18 years will be dosed on a body weight tiered regimen. Subjects > or = 35 kg will receive 10 mg twice daily for 7 days followed by 5 mg twice daily thereafter;<35 kg to 25 kg will receive 8 mg twice daily for 7 days followed by 4 mg twice daily thereafter; <25 to 18 kg will receive 6 mg twice daily for 7 days and then 3mg twice daily thereafter; <18 to 12 kg will receive 4 mg twice daily for 7 days and then 2 mg twice daily thereafter; <12 to 9 kg will receive 3 mg twice daily for 7 days and then 1.5 mg twice daily thereafter; <9 kg to 6 kg will receive 2 mg twice daily for 7 days and 1 mg twice daily thereafter; <6 kg to 5 kg will receive 1 mg twice daily for 7 days and 0.5 mg twice daily thereafter; <5 kg to 4 kg will receive 0.6 mg twice daily for 7 days and 0.3 mg twice daily thereafter.
    Intervention: Drug: Apixaban
  • Active Comparator: Standard of Care
    Subjects will receive a dose and dosing regimen of anticoagulation treatment based on usual and customary care per local practices.
    Intervention: Drug: Standard of Care
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: December 2, 2019)
250
Original Estimated Enrollment  ICMJE
 (submitted: June 4, 2015)
150
Estimated Study Completion Date  ICMJE April 30, 2023
Estimated Primary Completion Date April 30, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. 28 days to <18 years of age with a minimum weight of 4 kg at the time of randomization.
  2. Presence of an index VTE which is confirmed by imaging.
  3. Intention to manage the index VTE with anticoagulation treatment for at least 6 to 12 weeks.
  4. Subjects able to tolerate oral feeding, nasogastric (NG), gastric (G) feeding for at least 5 days.

Exclusion Criteria:

  1. Anticoagulant treatment for the index VTE for greater than 14 days prior to randomization.
  2. Thrombectomy, thrombolytic therapy, or insertion of a caval filter to treat the index VTE.
  3. A mechanical heart valve.
  4. Active bleeding or high risk of bleeding at the time of randomization.
  5. Intracranial bleed, including intraventricular hemorrhage, within 3 months prior to randomization.
  6. Abnormal baseline liver function at randomization.
  7. Inadequate renal function at the time of randomization.
  8. Platelet count <50×109 per L at randomization.
  9. Uncontrolled severe hypertension at the time of randomization.
  10. Use of prohibited concomitant medication at the time of randomization.
  11. Female subjects who are either pregnant or breastfeeding a child.
  12. Use of aggressive life-saving therapies such as ventricular assist devices (VAD) or extracorporeal membrane oxygenation (ECMO) at the time of enrollment.
  13. Unable to take oral or enteric medication via the NG or G tube.
  14. Known inherited or acquired antiphospholipid syndrome (APS).
  15. Known inherited bleeding disorder or coagulopathy with increased bleeding risk (eg, hemophilia, von Willebrand disease, etc.)
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE up to 17 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Pfizer CT.gov Call Center1-800-718-1021[email protected]
Listed Location Countries  ICMJE Australia,   Austria,   Canada,   Germany,   Israel,   Portugal,   Russian Federation,   Spain,   Ukraine,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02464969
Other Study ID Numbers  ICMJE B0661037
2014-002606-20 ( EudraCT Number )
CV185-325 ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Bristol-Myers Squibb
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date June 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP